A study of unprecedented scale has led researchers to identify four previously unknown genetic risk locations for primary sclerosing cholangitis, a liver disease that lacks effective medical therapy. A new article highlights the undertaking, which is the largest genome-wide association study of primary sclerosing cholangitis to date and a step toward providing breakthrough treatments for the unmet needs of primary sclerosing cholangitis patients.